Bortezomib reinduction chemotherapy in high‐risk ALL in first relapse: a report from the Children's Oncology Group

Summary While survival in paediatric acute lymphoblastic leukaemia (ALL) is excellent, survival following relapse is poor. Previous studies suggest proteasome inhibition with chemotherapy improves relapse ALL response rates. This phase 2 Children's Oncology Group study tested the hypothesis tha...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of haematology Jg. 186; H. 2; S. 274 - 285
Hauptverfasser:	Horton, Terzah M., Whitlock, James A., Lu, Xiaomin, O'Brien, Maureen M., Borowitz, Michael J., Devidas, Meenakshi, Raetz, Elizabeth A., Brown, Patrick A., Carroll, William L., Hunger, Stephen P.
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	England Blackwell Publishing Ltd 01.07.2019
Schlagworte:	acute lymphoblastic leukaemia Acute lymphoblastic leukemia acute lymphocytic leukaemia Adolescent Adult Bortezomib Bortezomib - administration & dosage Bortezomib - adverse effects Chemotherapy Child Child, Preschool Children Clinical trials Diagnosis Disease-Free Survival Female Hematology Humans Infant Leukemia Lymphoma Male Minimal residual disease Neoplasm, Residual Oncology paediatric leukaemia Precursor Cell Lymphoblastic Leukemia-Lymphoma - blood Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality proteasome inhibition Proteasome inhibitors Recurrence Survival Rate Time Factors proteasome inhibition acute lymphocytic leukaemia minimal residual disease acute lymphoblastic leukaemia paediatric leukaemia
ISSN:	0007-1048, 1365-2141, 1365-2141
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!